

AMENDMENTS TO THE SPECIFICATION

On page 1, after the title, please amend the cross-referencing paragraph as follows:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the United States national stage filing of corresponding international application number PCT/US2004/042710 filed December 20, 2004, which claims the benefit of and priority to U.S. Provisional Application No. 60/532,842, filed December 23, 2003, hereby incorporated by reference in its entirety all of which are hereby incorporated by reference in their entirety.

On page 18, please amend the paragraph at lines 16-23 as follows:

Other useful targeting moieties include analogs of somatostatin, which, for example, are Lanreotide (Nal-Cys-Thr-DTrp-Lys-Val-Cys-Thr-NH₂) (SEQ ID NO: 1), Octreotide (Nal-Cys-Thr-DTrp-Lys-Val-Cys-Thr-ol) (SEQ ID NO: 2), and Y³-Octreotate (DPhe-Cys-Tyr-DTrp-Lys-Thr-Cys-Thr-OH) (SEQ ID NO: 3). These analogs are described in the literature (*e.g.*, Potent Somatostatin Analogs Containing N-terminal Modifications, S. H. Kim, J. Z. Dong, T. D. Gordon, H. L. Kimball, S. C. Moreau, J.-P. Moreau, B.A. Morgan, W. A. Murphy and J. E. Taylor; Peptides: Chemistry, Structure and Biology Pravin T. P. Kaumaya, and Roberts S. Hodges (Eds.), Mayflower Scientific LTD., 1996, pgs 241-243.)

On pages 20-21, please amend the bridging paragraph at line 21 as follows:

In an exemplary embodiment, the targeting peptide Q is LHRH or an analog or derivative thereof. For example, it is well known in the art that position 6 of LHRH agonists may be substituted with different functional groups, such as, for example D-

Lysine. In a preferred embodiment, the targeting peptide Q is an LHRH analog of the formula PGlu-His-Trp-**W**-Tyr-DLys-**X**-**Y**-Pro-**Z** (SEQ ID NO: 4), wherein

W = Ser, NMeSer, or Thr.

X = Leu, NMeLeu, t-ButylGly.

Y = Arg, Arg(Et₂), Cit, Lys(isopropyl).

Z = Gly-NH₂, NHEthyl, Azagly-NH₂.

Linkers of the invention coupled to glycine and D-Lysine can be attached to the LHRH analog at position 6.